Malta: Developments in Article 126a Authorisations in Malta
Dr Anthia A Zammit discusses the latest developments in Article 126a Authorisations in Malta. The related authorisation procedure has changed since 1 October 2020. Article 126a is now considered as the last resort option, if no other type of authorisation procedure is available
EIPG: The role of pharmacy during Covid-19
The last webinar of 2020 chaired by executive director of EIPG, Mrs. Jane Nicholson, was held in conjunction with PIER and University College Cork on Tuesday 24th November 2020 on Advanced Therapy Medicinal Products. Professor Gino Martini, past EIPG president and Chief Scientist at the Royal Pharmaceutical Society reflects on the role of pharmacy during COVID-19. At a latest report published during November 2020, at Europol website, some of the key findings are related to Pharma sector and other activities involving pharmaceutical or health products
A new Strategic Agenda for cell-based interceptive medicine
The LifeTime Initiative has launched its ten years roadmap for research in the new area of cell-based interceptive medicine. The ambitious goal is to precisely map the trajectory of diseases in five main therapeutic areas up to the single cell level, in order to select the best available treatment for each patient
Updates on the activities of the EU’s Pharmaceutical Committee
The 90th meeting of the European Pharmaceutical Committee discussed the mandates of the ad-hoc working groups for vulnerabilities in the supply chain and for pharmaceuticals in the environment
Barriers to generic and biosimilar entry on the market
Secondary and divisional patents, patents thickets and patent linkage are just some examples of the many tools the innovator industry uses to delay the entry on the market of new generic and biosimilar drugs, explains a white paper published by Medicines for Europe
EIPG: Webinar on ATMPs and a new board in AEFI
The next EIPG webinar will be held in conjunction with PIER and University College Cork on Tuesday 24th November 2020 on Advanced Therapy Medicinal Products. A new Governing Board of the Spanish Association of Pharmacists in Industry appointed in the Ordinary General Assembly held last 15th October 2020
Towards the new EU Pharmaceutical Strategy
Many comments are coming from the different stakeholders to support the EU Commission in shaping the final contents of the new EU Pharmaceutical Strategy. Highlights from the contributions of the Dutch Parliament, PGEU and the MEP Interest Group on AMR
EIPG’s vision on Annex 1 to GMPs
The coordinator of the EIPG working group, Dr Francesco Boschi, discussed in a webinar the vision of the Association on the new Annex 1 to GMPs. Dr Boschi illustrated the comments EIPG forwarded in response to the second phase of consultation on the draft text
The EU Parliament approved the report on shortages of medicines
The report highlights priority actions needed to prevent supply chain disruptions that should be included by the EU Commission in its new Pharmaceutical Strategy
How the future of health systems may look like
In her speech on the State of the Union, president Ursula von der Leyen has illustrated the possible scenarios for the future of European health systems. Expansion of the roles for EMA and the ECDC and the creation of a European BARDA are among the main features. WHO Europe also expressed its views for future from the column of the The Lancet